Share on LinkedInShare on LinkedIn

ARTICLE · 29 SEPTEMBER 2017

Interpreting The On-Sale Bar Under The AIA

In Helsinn Healthcare S.A., v. Teva Pharmaceuticals USA, Inc., the Federal Circuit interpreted, for the first time, what constitutes an "on-sale" bar under 35 U.S.C. 102(a)(1) of the Leahy-Smith America Invents Act.

United StatesIntellectual Property

In Helsinn Healthcare S.A., v. Teva Pharmaceuticals USA, Inc., 855 F.3d 1356 (Fed. Cir. 2017), the Federal Circuit interpreted, for the first time, what constitutes an "on-sale" bar under 35 U.S.C. 102(a)(1) of the Leahy-Smith America Invents Act ("AIA"). Under the AIA, a person will not be entitled to a patent if "the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention," if such actions by an inventor are more than a year prior to the effective filing date of the invention. 35 U.S.C. 102(a)(1) (emphasis added).

Under the pre-AIA Section 102 of the statute, the "on sale" language is interpreted in a way that the on-sale bar applies if the patented product was subject of a commercial offer for sale, as understood under the law of contracts. See, Medicines Co. v. Hospira, Inc., 827 F.3d 1363, 1373 (Fed. Cir. 2016). Courts have held

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from